TTS President Prof. Mehmet Haberal and TTS leadership at CAST 2019
Prof. Mehmet Haberal is presented with Honorary Fellowship of the Indian Society of Organ Transplantation
The Asian Society of Transplantation (AST) was formed in 1981 and its 16th Congress was organized in New Delhi, India on 29 September – 2 October, 2019. The Congresses of the Asian Society of Transplantation (CAST) are designed to bring to the Asian transplant community an update on the state of the art of the principles and practice of organ donation and transplantation and to provide a forum for sharing best practices and innovations. This congress followed in this tradition by putting together a rich scientific programme to meet these goals. Jointly organized by the 30th Annual Conference of the Indian Society of Organ Transplantation (ISOT), the 5th Centre for Liver and Biliary Sciences (CLBS) Symposium, the Annual Meeting of Indian Society for Heart and Lung Transplantation (INSHLT), and the 16th International Congress of the International Society of Vascularized Composite Allotransplants (ISVCA), a Section of The Transplantation Society, the congress proved to be a great success, drawing 1300 participants from all corners of the world.
Prof. Haberal highlights the importance of Deceased Organ Donation during his lecture
Prof. Haberal was invited as the guest of honor, and in addition to several lectures and a role on a deceased donation panel, he was requested to make the opening remarks at the inauguration of the Congress. During his speech, he reiterated the importance of deceased organ donation as a solution to unethical organ transplantation activity as well as the ultimate goal of giving a second chance at life for the many patients with end stage organ failure. Prof. Haberal was then presented with the First Honorary Fellowship of the Indian Society for Organ Transplantation, after which he presented 30 new members with their fellowship certificates, among whom was TTS President-Elect Dr. Marcelo Cantarovich, who also received Honorary Fellowship of ISOT. The meeting, which was endorsed by The Transplantation Society, was also attended by several members of the society’s Executive Council and the India Relations Committee who met with ISOT leadership to discuss current transplant practices in India, and important future steps.
The India Relations Committee meets with ISOT leadership to discuss current transplant practices in India, and important future steps
Transplantation - WEEK'S MOST DOWNLOADED PAPERCLICK HERE TO VIEW (OPEN ACCESS)
TTS-ILTS PAIRED TRANSPLANT CENTERS PROGRAM
DEADLINE JANUARY 1, 2020
The TTS-ILTS Paired Transplant Centers Program is a collaboration between The Transplantation Society (TTS) and the International Liver Transplantation Society (ILTS) supporting new liver transplant programs in emerging countries.VISIT WWW.TTS-ILTS.ORG FOR FULL DETAILS
Just Released - Transplantation - October Issue
Where is the shortage of liver transplants taking us and have changes to allocation made any differences? Can we improve the organ donor supply with oxygen? Are there practical ways to lead us to xenotransplantation or organ tolerance? Should you operate on the heart while doing a lung transplant? Can we improve the utilisation of living donation through interaction with deceased donor allocation systems? There are many more questions asked and answered in this issue of Transplantation.
Transplantation Direct - October Issue - Now Available
The October issue of Transplantation Direct is out in open-access. Several topics in kidney transplantation are included in this issue, including the promotion of living donation in elderly patients, the aspect of elevated blood pressure in living donors, dealing with monoclonal gammopathy of undetermined significance in recipients, and recommendations regarding treatment options in cases of anti-rabbit, anti-thymocyte globulin antibody development. In liver transplantation, we present articles related to making decisions on proceeding with liver transplantation alone versus waiting for a simultaneous liver-kidney transplant in patients requiring renal replacement therapy, and on using bortezomib against refractory antibody-mediated rejection after ABO incompatible living donor liver transplantation. We also publish a study on outcomes in "Milan-out criteria" liver transplant recipients. Finally, we publish a survey on perceptions of safety during travel associated with organ procurement team activity, which is especially important is this era of aggressive organ utilization due to the organ shortage. Please visit our Transplantation Direct website for full article details.
Transplantation - Highlighted Article
Dr. Andrea Schlegel, Editorial Fellow, Transplantation
Survival Benefit of Liver Transplantation for Hepatocellular Carcinoma
Kanneganti M, Mahmud N, Kaplan DE, et al.
Transplantation: Publish Ahead of Print DOI: 10.1097/TP.0000000000002816
In context of an increasing number of patients with an alcoholic or non-alcoholic liver disease, a growing rate of hepatocellular carcinoma (HCC) as primary or secondary indication for liver transplantation (LT) has been described. Although the superior outcomes after liver transplantation for HCC patients is widely known, there was a lack of multifactorial analyses comparing LT, liver resection and radiofrequency ablation (RFA). Authors of this retrospective cohort study have now compared outcomes following such three treatment modalities in a large cohort of 2129 patients at 50-69years of age, between 2008 and 2016. The majority of parameters were equally distributed among the different groups and patients with a MELD score of >15 points at diagnosis were excluded. Almost one third of patients (26,7%; n=658/2129) received a LT, and 244 underwent liver resection (11.5%), while the majority received an ablation of their HCC lesion (n=1,317, 61.59%).
Expectedly, the multivariate analysis confirmed earlier reports with a higher risk of death in the resection and ablation group compared to the liver transplant group (HR: 5.42 and 5.50).
Interestingly, patients who underwent LT were identified with a limited survival benefit of 0.02-0.03 and 0.32-0.42 years, one and three years after LT respectively, with a marginal increase to 1.04-1.24 years at five years after treatment, when compared to patients with resection or ablation. Although authors confirm here earlier findings and demonstrate a benefit of LT over other treatment modalities, the benefit appears rather small due to the limited tumour risk in all three cohorts (mainly single lesions with 2-3cm diameter). Further studies are therefore awaited to link tumour risk factors with donor or graft parameters with subsequent different levels of reperfusion injury, which may expose liver recipients to a higher risk of delayed graft function with subsequent HCC recurrence.
OCTOBER 23 - Webinar announcement
TITLE: PSYCHOSOCIAL ASPECTS OF VCA
WEDNESDAY, OCTOBER 23, 2019 - 10:00 AM EDT (MONTREAL TIME)
This webinar will highlight the psychosocial challenges that potential recipients face and the importance of the evaluation and support on outcomes of VCA.CLICK HERE TO SIGNUP AND LEARN MORE
IN THE NEWS
Trio Wins Nobel Prize In Physiology Or Medicine For Work On Cells And Oxygen
Oct. 7 - Three scientists who made important discoveries about how cells sense and adapt to different oxygen levels have won the Nobel Prize in physiology or medicine, in the first announcement of Nobel winners for 2019.
Scientist designs 'express courier service' for immune cells
Oct. 4 - A researcher who is currently doing his post-doctoral training at Stanford University, has successfully invented a novel transfection method to deliver DNA into immune cells with minimal stress on these cells. This new technique is expected to boost DNA-based cancer immunotherapy by significantly improving the process of generating high-quality genetically modified immune cells.
Osteochondral autologous transplantation found efficacious for Freiberg infraction
Oct. 4 - Compared with dorsiflexion closing wedge metatarsal osteotomy, investigators found osteochondral autologous transplantation was safe and effective for the treatment of Freiberg infraction in an athletic population.
5-Year Survival High for HIV+ to HIV+ Kidney Transplant
Oct. 4 - HIV positive individuals have high rates of 5-year overall survival and kidney graft survival after receiving a transplant from a deceased donor with HIV, according to new research conducted in South Africa and published October 3 in the New England Journal of Medicine.
Tiny Bubbles In Our Bodies Could Be Used To Deliver Cancer-Fighting Drugs
Oct. 4 - Researchers from Michigan State University and Stanford University are suggesting a new, novel approach to cancer treatment. Tiny, nano-sized bubbles naturally produced by cells in our bodies could be used to efficiently transport cancer-killing drugs and genes to tumors in patients’ bodies.
Upcoming Meetings and ANNOUNCEMENTS
TOND-TDTD - STARTS TODAY, October 10-11, 2019!
The 3rd Joint Meeting of the Turkish Transplantation Society and the Turkic World Transplantation Society will be held in Tashkent, Uzbekistan on October 10-11, 2019. The Scientific and Local Organizing Committees, comprised of international transplantation leaders, have developed a program that reflects current problems and represents a collection of scientific, educational, and practical information. The meeting will be an exciting opportunity for transplant professionals to share their expertise as well as their concerns regarding the development of the field in their own countries.
International Transplantation Science Meeting 2019
ITS 2019 is set for Nov. 10-13 in Clearwater Beach, Florida. Keynote speakers include Katherine High, President and Head of R&D at Spark Therapeutics, and Ronald Germain, chief of Laboratory of Immune System Biology and Lymphocyte Biology Section at the National Institute of Allergy and Infectious Diseases National Institutes of Health.
ISHLT2020 - Upcoming Abstract Submission Deadline!
We Want Your Best Research
The Abstract Submission Site for ISHLT2020 is NOW OPEN
ISHLT invites you to submit your best science for their 40th annual meeting, to be held April 22 – 25 in Montrèal, Canada.
ISHLT’s annual meeting is the largest global, multidisciplinary gathering of researchers and clinicians dedicated to helping patients with advanced heart or lung disease. Last year, more than 4,000 people attended, representing 52 countries and 15 disciplines.
Submission Deadline: October 15, 2019 11:59 ET (North America)
Status Notification: December 10, 2019
For more information on the submission process and policies, visit the ISHLT2020 Call for Abstracts website
On se voit à Montréal
We’ll see you in Montrèal.
IXA 2019 - STARTS TODAY!
24th Annual SPLIT Meeting
SPLIT is an official section of The Transplantation Society